Jasper Therapeutics (JSPR) Stock Forecast & Price Target

Compare

933 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JSPR Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Jasper

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JSPR Stock 12 Month Forecast

Average Price Target

$39.80

▲(598.25%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $39.80 with a high forecast of $65.00 and a low forecast of $15.00. The average price target represents a 598.25% change from the last price of $5.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","35":"$35","66":"$66","19.5":"$19.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,19.5,35,50.5,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,9.966153846153846,14.552307692307693,19.138461538461538,23.724615384615383,28.31076923076923,32.89692307692308,37.48307692307692,42.06923076923077,46.65538461538462,51.24153846153846,55.82769230769231,60.41384615384616,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,8.027692307692307,10.675384615384615,13.323076923076922,15.970769230769228,18.618461538461535,21.266153846153845,23.91384615384615,26.561538461538458,29.209230769230764,31.85692307692307,34.504615384615384,37.15230769230769,{"y":39.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.12,6.86,7.6,8.34,9.08,9.82,10.56,11.3,12.040000000000001,12.780000000000001,13.52,14.260000000000002,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.3,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.99,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.96,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.14,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$39.80

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kostas BiliourisBMO Capital

BMO Capital

$15

Buy

163.16%

Upside

Reiterated

05/27/25

Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market

Jay OlsonOppenheimer

Oppenheimer

$80→$65

Buy

1040.35%

Upside

Reiterated

05/15/25

Jasper Therapeutics price target lowered to $65 from $80 at OppenheimerJasper Therapeutics price target lowered to $65 from $80 at Oppenheimer

Trung HuynhUBS

UBS

$38→$33

Buy

478.95%

Upside

Reiterated

05/13/25

Jasper Therapeutics price target lowered to $33 from $38 at UBSJasper Therapeutics price target lowered to $33 from $38 at UBS

Emily BodnarH.C. Wainwright

H.C. Wainwright

$40

Buy

601.75%

Upside

Reiterated

05/13/25

Promising Advancements in Jasper Therapeutics' Briquilimab Programs Highlight Market Potential

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/13/25

Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating

Gregory RenzaRBC Capital

RBC Capital

$48→$46

Buy

707.02%

Upside

Reiterated

05/12/25

Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Jasper Therapeutics (JSPR)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/12/25

TD Cowen Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

03/03/25

Cantor Fitzgerald reiterates Overweight Rating on Jasper Therapeutics (JSPR)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Jasper Therapeutics (NASDAQ: JSPR).

Silvan TuerkcanCitizens JMP

Citizens JMP

$70

Buy

1128.07%

Upside

Reiterated

03/03/25

Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab's Phase 2b Program

Justin ZelinBTIG

BTIG

$64

Buy

1022.81%

Upside

Reiterated

03/02/25

Analysts' Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$80

Buy

1303.51%

Upside

Reiterated

03/02/25

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$65

Buy

1040.35%

Upside

Reiterated

12/24/24

We shared this last week in our ’25 outlook and accompanying webinar, but given the proximity to data and importance to JSPR – we want to send a separate note to make sure it didn’t get missed.

Tim ChiangCapital One Financial

Capital One Financial

$55

Buy

864.91%

Upside

Assigned

10/23/24

Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kostas BiliourisBMO Capital

BMO Capital

$15

Buy

163.16%

Upside

Reiterated

05/27/25

Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market

Jay OlsonOppenheimer

Oppenheimer

$80→$65

Buy

1040.35%

Upside

Reiterated

05/15/25

Jasper Therapeutics price target lowered to $65 from $80 at OppenheimerJasper Therapeutics price target lowered to $65 from $80 at Oppenheimer

Trung HuynhUBS

UBS

$38→$33

Buy

478.95%

Upside

Reiterated

05/13/25

Jasper Therapeutics price target lowered to $33 from $38 at UBSJasper Therapeutics price target lowered to $33 from $38 at UBS

Emily BodnarH.C. Wainwright

H.C. Wainwright

$40

Buy

601.75%

Upside

Reiterated

05/13/25

Promising Advancements in Jasper Therapeutics' Briquilimab Programs Highlight Market Potential

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/13/25

Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating

Gregory RenzaRBC Capital

RBC Capital

$48→$46

Buy

707.02%

Upside

Reiterated

05/12/25

Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Jasper Therapeutics (JSPR)

Yaron WerberTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/12/25

TD Cowen Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

03/03/25

Cantor Fitzgerald reiterates Overweight Rating on Jasper Therapeutics (JSPR)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Jasper Therapeutics (NASDAQ: JSPR).

Silvan TuerkcanCitizens JMP

Citizens JMP

$70

Buy

1128.07%

Upside

Reiterated

03/03/25

Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab's Phase 2b Program

Justin ZelinBTIG

BTIG

$64

Buy

1022.81%

Upside

Reiterated

03/02/25

Analysts' Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$80

Buy

1303.51%

Upside

Reiterated

03/02/25

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$65

Buy

1040.35%

Upside

Reiterated

12/24/24

We shared this last week in our ’25 outlook and accompanying webinar, but given the proximity to data and importance to JSPR – we want to send a separate note to make sure it didn’t get missed.

Tim ChiangCapital One Financial

Capital One Financial

$55

Buy

864.91%

Upside

Assigned

10/23/24

Buy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic Advancements

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jasper Therapeutics

1 Month

xxx

Success Rate

6/10 ratings generated profit

Average Return

+6.30%

assigned a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +6.30% per trade.

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

+11.18%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.18% per trade.

1 Year

Emily BodnarH.C. Wainwright

Success Rate

3/8 ratings generated profit

Average Return

-33.09%

reiterated a buy rating 26 days ago

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -33.09% per trade.

2 Years

xxx

Success Rate

3/8 ratings generated profit

Average Return

-32.45%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -32.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JSPR Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Feb 25

Mar 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JSPR has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JSPR average Analyst price target in the past 3 months is 39.80.

Each month's total comprises the sum of three months' worth of ratings.

JSPR Financial Forecast

JSPR Earnings Forecast

Next quarter’s earnings estimate for JSPR is -$1.33 with a range of -$1.55 to -$0.76. The previous quarter’s EPS was -$1.41. JSPR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.75% of the time in the same period. In the last calendar year JSPR has Outperformed its overall industry.

No data currently available

JSPR Sales Forecast

Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.82% of the time in the same period. In the last calendar year JSPR has Preformed in-line its overall industry.

JSPR Stock Forecast FAQ

What is JSPR’s average 12-month price target, according to analysts?

Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 39.80.

What is JSPR’s upside potential, based on the analysts’ average price target?

Jasper Therapeutics has 598.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JSPR a Buy, Sell or Hold?

Jasper Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Jasper Therapeutics’s price target?

The average price target for Jasper Therapeutics is 39.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $15.00. The average price target represents 598.25% Increase from the current price of $5.7.

What do analysts say about Jasper Therapeutics?

Jasper Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of JSPR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

JSPR Analyst Ratings

JSPR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jasper Therapeutics

JSPR Analyst Recommendation Trends

JSPR Financial Forecast

JSPR Earnings Forecast

JSPR Sales Forecast

JSPR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts